CA3005088A1 - Azithromycin derivatives with epithelial barrier enhancement properties - Google Patents
Azithromycin derivatives with epithelial barrier enhancement properties Download PDFInfo
- Publication number
- CA3005088A1 CA3005088A1 CA3005088A CA3005088A CA3005088A1 CA 3005088 A1 CA3005088 A1 CA 3005088A1 CA 3005088 A CA3005088 A CA 3005088A CA 3005088 A CA3005088 A CA 3005088A CA 3005088 A1 CA3005088 A1 CA 3005088A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- oxy
- oxa
- oxo
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1520419.1 | 2015-11-19 | ||
| GBGB1520419.1A GB201520419D0 (en) | 2015-11-19 | 2015-11-19 | Compounds |
| PCT/EP2016/078360 WO2017085329A1 (en) | 2015-11-19 | 2016-11-21 | Azithromycin derivatives with epithelial barrier enhancement properties |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3005088A1 true CA3005088A1 (en) | 2017-05-26 |
Family
ID=55133040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3005088A Pending CA3005088A1 (en) | 2015-11-19 | 2016-11-21 | Azithromycin derivatives with epithelial barrier enhancement properties |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10723752B2 (https=) |
| EP (2) | EP3377511B1 (https=) |
| JP (2) | JP6849896B2 (https=) |
| KR (2) | KR20240157138A (https=) |
| CN (2) | CN108290919B (https=) |
| CA (1) | CA3005088A1 (https=) |
| CY (1) | CY1123418T1 (https=) |
| DK (1) | DK3377511T3 (https=) |
| ES (1) | ES2810703T3 (https=) |
| GB (1) | GB201520419D0 (https=) |
| HR (1) | HRP20201246T1 (https=) |
| HU (1) | HUE050307T2 (https=) |
| LT (1) | LT3377511T (https=) |
| PL (1) | PL3377511T3 (https=) |
| PT (1) | PT3377511T (https=) |
| RS (1) | RS60698B1 (https=) |
| SI (1) | SI3377511T1 (https=) |
| SM (1) | SMT202000426T1 (https=) |
| WO (1) | WO2017085329A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201520419D0 (en) | 2015-11-19 | 2016-01-06 | Epi Endo Pharmaceuticals Ehf | Compounds |
| KR20220156570A (ko) | 2020-03-12 | 2022-11-25 | 조에티스 서비시즈 엘엘씨 | 면역조절성 유레아 아잘라이드 |
| AU2022343476B2 (en) * | 2021-09-07 | 2025-02-20 | Zoetis Services Llc | Immunomodulating azalides |
| CN121038797A (zh) | 2023-03-22 | 2025-11-28 | 艾比恩多制药有限责任公司 | 用于治疗嗜酸性粒细胞相关疾病的阿奇霉素衍生物 |
| GB202404587D0 (en) | 2024-03-28 | 2024-05-15 | Epiendo Pharmaceuticals Ehf | Chemical forms |
| GB202412461D0 (en) | 2024-08-23 | 2024-10-09 | Epiendo Pharmaceuticals Ehf | Medial use |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3725385A (en) | 1970-11-02 | 1973-04-03 | Abbott Lab | Process for the demethylation of 3-amino macrolides |
| HRP20010018A2 (en) * | 2001-01-09 | 2002-12-31 | Pliva D D | Novel anti-inflammatory compounds |
| AU2003219770B2 (en) * | 2002-02-15 | 2008-10-09 | Merckle Gmbh | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
| RU2330858C2 (ru) | 2002-07-08 | 2008-08-10 | Глаксомитклайн Истраживацки Центар Загреб Д.О.О. | Новые соединения, составы и способы лечения воспалительных заболеваний и состояний |
| ITMI20022292A1 (it) | 2002-10-29 | 2004-04-30 | Zambon Spa | 9a-azalidi ad attivita' antiinfiammatoria. |
| GB0310984D0 (en) * | 2003-05-13 | 2003-06-18 | Glaxo Group Ltd | Novel compounds |
| US7767797B1 (en) * | 2004-09-30 | 2010-08-03 | Synovo Gmbh | Macrocyclic compounds and methods of use thereof |
| PT1851236E (pt) | 2005-01-13 | 2010-10-25 | Glaxosmithkline Zagreb | Macrólidos com actividade anti-inflamatória |
| EP1841776B1 (en) * | 2005-01-13 | 2008-12-31 | GlaxoSmithKline istrazivacki centar Zagreb d.o.o. | Decladinosyl-macrolides with anti-inflammatory activity |
| CN1837225A (zh) | 2005-08-23 | 2006-09-27 | 济南思创生物技术有限公司 | 阿奇霉素衍生物及其制法和药物应用 |
| RU2455308C2 (ru) | 2006-05-01 | 2012-07-10 | Тайсо Фармасьютикал Ко., Лтд. | Макролидные производные |
| CN101074251B (zh) * | 2007-06-22 | 2011-06-15 | 山东大学 | 阿奇霉素4＂-氨甲酸酯衍生物、制备方法及其药物组合物 |
| WO2009006403A2 (en) * | 2007-06-29 | 2009-01-08 | Georgia Tech Research Corporation | Non-peptide macrocyclic histone deacetylase (hdac) inhibitors and methods of making and using thereof |
| WO2010086351A1 (en) * | 2009-01-30 | 2010-08-05 | Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. | 3'-n-substituted 9-deoxo-9a-methyl-9a-aza-homoerythromycin having antimalarial activity |
| CA2814333A1 (en) * | 2010-10-10 | 2012-04-19 | Synovo Gmbh | Anti-inflammatory macrolides |
| GB201105633D0 (en) * | 2011-04-01 | 2011-05-18 | Norbrook Lab Ltd | Antibotic compounds |
| EP2831083A4 (en) * | 2012-03-27 | 2016-03-09 | Michael W Burnet | INFLAMMATORY MAKROLIDE |
| AU2014252462A1 (en) | 2013-04-10 | 2015-10-01 | Probiotic Pharmaceuticals Aps | Azithromycin antimicrobial derivatives with non-antibiotic pharmaceutical effect |
| GB201520419D0 (en) | 2015-11-19 | 2016-01-06 | Epi Endo Pharmaceuticals Ehf | Compounds |
-
2015
- 2015-11-19 GB GBGB1520419.1A patent/GB201520419D0/en not_active Ceased
-
2016
- 2016-11-21 KR KR1020247035784A patent/KR20240157138A/ko active Pending
- 2016-11-21 JP JP2018526129A patent/JP6849896B2/ja active Active
- 2016-11-21 KR KR1020187017001A patent/KR102724114B1/ko active Active
- 2016-11-21 HR HRP20201246TT patent/HRP20201246T1/hr unknown
- 2016-11-21 CN CN201680067151.6A patent/CN108290919B/zh active Active
- 2016-11-21 RS RS20200947A patent/RS60698B1/sr unknown
- 2016-11-21 WO PCT/EP2016/078360 patent/WO2017085329A1/en not_active Ceased
- 2016-11-21 CN CN202210535850.6A patent/CN114933620B/zh active Active
- 2016-11-21 LT LTEP16804720.7T patent/LT3377511T/lt unknown
- 2016-11-21 DK DK16804720.7T patent/DK3377511T3/da active
- 2016-11-21 EP EP16804720.7A patent/EP3377511B1/en active Active
- 2016-11-21 US US15/777,223 patent/US10723752B2/en active Active
- 2016-11-21 SM SM20200426T patent/SMT202000426T1/it unknown
- 2016-11-21 HU HUE16804720A patent/HUE050307T2/hu unknown
- 2016-11-21 EP EP20172534.8A patent/EP3708573A1/en active Pending
- 2016-11-21 ES ES16804720T patent/ES2810703T3/es active Active
- 2016-11-21 SI SI201630881T patent/SI3377511T1/sl unknown
- 2016-11-21 PL PL16804720T patent/PL3377511T3/pl unknown
- 2016-11-21 CA CA3005088A patent/CA3005088A1/en active Pending
- 2016-11-21 PT PT168047207T patent/PT3377511T/pt unknown
-
2020
- 2020-06-18 US US16/904,593 patent/US11236120B2/en active Active
- 2020-08-12 CY CY20201100750T patent/CY1123418T1/el unknown
-
2021
- 2021-02-09 JP JP2021019109A patent/JP7256558B2/ja active Active
- 2021-12-15 US US17/551,223 patent/US12049477B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12049477B2 (en) | Azithromycin derivatives with epithelial barrier enhancement properties | |
| KR102825246B1 (ko) | 테르페닐 화합물의 신규 염 | |
| CN106488915B (zh) | 作为lsd1抑制剂的环丙胺 | |
| KR102450071B1 (ko) | 마크로시클릭 광범위 항생제 | |
| CN111511737B (zh) | 用于治疗细菌感染的单环β-内酰胺化合物 | |
| CN116496318A (zh) | 一种杂环衍生物及其组合物和药学上的应用 | |
| TW202110831A (zh) | 吡啶酮類衍生物、其製備方法及其在醫藥上的應用 | |
| KR20110099791A (ko) | 항염증 마크롤리드 | |
| JP2018529696A (ja) | ヒドロキシアルキルチアジアゾール誘導体 | |
| CN101117336A (zh) | 7-(4-肟基-3-氨基-1-哌啶基)喹啉羧酸衍生物及其制备方法 | |
| HK40037271A (en) | Azithromycin derivatives with epithelial barrier enhancement properties | |
| EP4683641A1 (en) | Azithromycin derivatives for use in the treatment of eosinophil-related diseases | |
| HK1255270B (en) | Azithromycin derivatives with epithelial barrier enhancement properties | |
| CN110392684A (zh) | 新型杂环化合物及其在预防或治疗细菌感染中的用途 | |
| JP2011518799A (ja) | ２’−ｏ，３’−ｎ−橋かけマクロライド | |
| CN101450947B (zh) | 7-(3-肟基-4-氨基-4-烷基-1-哌啶基)喹啉羧酸衍生物及其制备方法 | |
| CN103739591A (zh) | 7-(3-酰胺基-4-甲肟基-1-哌啶基)氟喹诺酮羧酸及其制备方法 | |
| JP2023505389A (ja) | マクロライド化合物及びその慢性呼吸器疾患の治療用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20211122 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20240927 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241023 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241023 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241023 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20241213 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20241213 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D156 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION SENT - EXAMINATION ON HOLD Effective date: 20250114 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250114 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D11-D131 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (RCE) RECEIVED Effective date: 20250321 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250321 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250402 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D148 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (NOA/CNOA) DETERMINED COMPLIANT Effective date: 20250724 Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D174 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250724 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250724 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250724 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250724 Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250724 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD Year of fee payment: 9 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251022 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251022 |